Current Affairs - Science - Discussion

Rasonque (daraxonrasib) was approved by the U.S. Food and Drug Administration (FDA) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma. Developed by Revolution Medicines, Inc., Rasonque is a RAS inhibitor that targets multiple forms of the RAS protein, a key driver of tumour growth. It is administered as a once-daily tablet and is intended for patients who have received at least one prior systemic therapy and are not candidates for multiagent systemic therapy. In a randomised clinical trial involving 500 adults, the treatment improved median overall survival to 13.2 months compared with 6.7 months with standard chemotherapy.